Key result
Poststroke oral anticoagulation therapy was associated with a lower risk of recurrent thromboembolic events compared with no antithrombotic therapy (HR 0.81; 95% CI 0.73-0.89).
Why the study?
Does poststroke oral anticoagulation therapy reduce recurrent thromboembolic events in patients with atrial fibrillation presenting with ischemic stroke?
Cohort (n=30,626)
Yes
Does poststroke oral anticoagulation therapy reduce recurrent thromboembolic events in patients with atrial fibrillation presenting with ischemic stroke?
Hazard Ratio: 0.81 (95% CI 0.73–0.89)
Absolute Event Rate: 17.5% vs 21.5%
In high-risk patients with atrial fibrillation who survive an ischemic stroke, poststroke oral anticoagulation is associated with a significantly lower risk of recurrent thromboembolic events without increasing bleeding complications compared to no antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Supports poststroke OAC consideration in AF; leaves open need for randomized confirmation.
Gundlund et al. (2018) conducted a cohort in Atrial fibrillation presenting with ischemic stroke (n=30,626). Poststroke oral anticoagulation (OAC) therapy vs. No poststroke antithrombotic therapy was evaluated on Recurrent thromboembolic events (HR 0.81, 95% CI 0.73-0.89). Poststroke oral anticoagulation therapy was associated with a lower risk of recurrent thromboembolic events compared with no antithrombotic therapy (HR 0.81; 95% CI 0.73-0.89).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: